

Nurosene Announces DTC Eligibility

TORONTO, ON, September 27, 2021 – Nurosene Health Inc. (“Nurosene” or the “Company”) (CSE: MEND) (Frankfurt: 8TV) (OTC: MNNDP), a healthtech company focused on building a generation of better brains, announces that it has received Depository Trust & Clearing Corporation (“DTC”) eligibility.

DTC eligibility allows Nurosene’s shares to be electronically cleared and settled, which will streamline the process of trading, enhance liquidity, and provide direct access to investors in the U.S. OTC capital markets. DTC is a subsidiary of the Depository Trust and Clearing Corporation (DTCC), one of the world’s largest securities depositories that manages the electronic clearing and settlement of publicly traded companies.

“Achieving DTC eligibility allows for better accessibility and simplicity in trading for our investors in the United States, as well as providing for greater liquidity of our common shares,” stated Ranj Bath, CEO of Nurosene. “Nurosene continues to focus on our forward growth trajectory and our plans to expand our stakeholder community to facilitate in developing integrated mental health solutions.”

About Nurosene

Nurosene provides individuals with tools and technology that empower them to take control of their mental wellness. Our mission is to build the next generation of better, healthier brains by leveraging technological advancements in AI and machine learning. With our team of experts and partners, Nurosene is positioned at the leading edge of critical research and innovations, striving to disrupt traditional mental wellness treatments. The company is based in Toronto, Ontario.

For more information, visit www.nurosene.com.

For further information:

Blake Sing
Chief Financial Officer
investors@nurosene.com
(416) 859-8838

KCSA Strategic Communications:
Valter Pinto
Managing Director
Valter@KCSA.com
(212) 896-1254

Forward-Looking Statements

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation which is based upon Nurosene's current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact.

Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, Nurosene does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for Nurosene to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements in Nurosene Final Long Form Prospectus dated May 20, 2021 and filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in Nurosene Final Long Form Prospectus could cause actual events or results to differ materially from those described in any forward-looking information.

The CSE does not accept responsibility for the adequacy or accuracy of this release.